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Introduction: The focus of the pharmaceutical industry has dramatically shifted in the past number of years. Traditional drugs were 
synthesised using chemical reactions have been replaced by recombinant glycoprotein molecules. These potential recombinant 
glycoprotein therapeutics display oligosaccharide structures on their surfaces that are recognised by their target host. The specific glycan 
moieties on the surface of the molecules vary dramatically and have a large impact on the efficacy of the drug.  The development of 
bioanalytical tools to identify and separate the species of glyco-forms present in a preparation of the glycoprotein therapeutic will 
significantly help to advance the quality and effectiveness of recombinant glycoprotein molecules. Traditionally lectins, isolated from 
plants, had been used to profile sugar species displayed on glycoproteins. I have explored the use of prokaryotic chitin binding proteins 
(CBPs) to investigate structures on glycoproteins.  
 
Objectives: To develop novel carbohydrate binding protein bio-ligands, based on natural chitin binding properties for the ultimate analysis 
of glycoprotein therapeutics. 
 
Cloning: The chitin binding 
protein CBP21 from Serratia 
marcescens (Suzuki et al. 1998) 
w a s a m p l i f i e d f r o m S . 
marcescens koln genomic DNA 
using PCR. The gene was 
subsequently cloned into an e.coli 
expression vector pQE60. This 
vector incorporates a poly 
histidine tag onto the C terminus 
of the protein, there is also an 
IPTG inducible T5/lac promoter. 
The vector was named pRL11. 
 
Expression: Freshly transformed 
cells can vary widely as to the 
amount of protein produced. 
Clonal selection was used to 
select a clone producing high 
amounts of soluble protein 
(Dahlroth, et al. 2006). KRX 
clone was ultimately selected for 
recombinant protein production. 
It was possible to produce 6mg of 
protein from a 400ml culture 
using this clone. 
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Figure 1: pRL11. The multiple cloning sites are indicated. 
The 6xHis (blue) is located downstream from the MSC 
which in turn is located downstream from the T5 promoter/
lac operon (yellow). The Ampicillan resistance gene is 
shown in red.  
Figure 2: Colony blot analysis of C-terminally tagged 
CBP21 for clonal selection. Positive and negative 
controls are indicated. 
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Figure 3: IMAC purification profile of CBP21. 
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Future Work: ELLA analysis of CBP21 using enzyme treated glycoproteins to pinpoint the specific interactions of CBP21. Site directed 
mutagenesis of CBP21 to alter the binding specificity. Cloning, expression and profiling of CBP21 homologues. Further characterisation 
of glycoprotein binding molecules using iCT 2000, Biacore and NMR.  
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Characterisation: Following the purification of CBP21 its 
activity was tested by checking the affinity of CBP21 to 
chitin, avicel (cellulose) and chitosan (de-acetylated chitin). 
Binding of the insoluble substrates was assessed in column 
by an incubation stage followed by washing steps. Samples 
were visualised using SDS-PAGE. 
Figure 4: A-Chitin binding assay, B-Avicel binding assay, C-Chitosan binding assay. Lane 1; Broad range 
protein ladder, Lane 2; Crude CBP21 sample, Lane 3; Column flowthrough, Lane 4; Wash 1, Lane 5; Wash 
2, Lane 6; Boiled substrate sample. 
Discussion: Further ELLA 
analysis must be carried out 
to identify the specific 
sugars that CBP21 interacts 
directly with. Interestingly it 
can be seen from the  sugar 
Preliminary ELLA analysis: 
Enzyme linked lectin assays 
(ELLA) were used to profile the 
interactions of the recombinant 
p r o t e i n  C B P 2 1  w i t h 
commercial glycoproteins.  
Figure 6: Sugar Inhibition ELLAs were 
used to pinpoint the sugar  species that 
CBP21 interacts with.  
Figure 5: Profiling of CBP21 interactions with 
commercial glycoproteins compared to GSLII, 
a commercial lectin known to bind terminal N-
acetyl-D-glucosamine (GlcNAc) 
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Purification: The incorporation of 
a 6-His poly Histidine tag at the C-
terminus of the protein allowed for 
purification using Immobilised 
metal affinity chromatography 
(IMAC).  
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inhibition ELLA studies that Mannose and galactose inhibit 
CBP21 interaction with the commercial  glycoproteins to a 
greater extent than GlcNAc. 
 
